bioAffinity Technologies closes $4M registered direct offering and concurrent private placement

bioAffinity Technologies, Inc.

Entered Oct 8, 2026 securities purchase agreement for 116,545 shares at $6.122 and pre-funded warrants for 536,836 shares at $6.115.
Concurrent private placement issued warrants for up to 980,072 shares at $6.122, exercisable after stockholder approval and expiring five years later.
Gross proceeds approximately $4 million; closing occurred Oct 9, 2026; net proceeds for working capital and CyPath Lung sales support.
WallachBeth Capital LLC is sole placement agent; cash fee 7.5% of gross proceeds, $70,000 expenses, and warrants for 19,602 shares at $6.122.
Company suspended ATM prospectus supplement dated May 27, 2025 under sales agreement with Placement Agent; sales agreement remains in effect.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.